Forebrain delta opioid receptors regulate the response of delta agonist in models of migraine and opioid-induced hyperalgesia.
Analgesics, Opioid
/ pharmacology
Animals
Benzamides
/ pharmacology
Cortical Spreading Depression
/ drug effects
Disease Models, Animal
GABAergic Neurons
/ drug effects
Hyperalgesia
/ chemically induced
Mice
Mice, Knockout
Migraine Disorders
/ chemically induced
Nitroglycerin
Piperazines
/ pharmacology
Prosencephalon
/ drug effects
Receptors, Opioid, delta
/ agonists
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 10 2020
19 10 2020
Historique:
received:
13
05
2020
accepted:
30
09
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Delta opioid receptor (DOR) agonists have been identified as a promising novel therapy for headache disorders. DORs are broadly expressed in several peripheral and central regions important for pain processing and mood regulation; and it is unclear which receptors regulate headache associated symptoms. In a model of chronic migraine-associated pain using the human migraine trigger, nitroglycerin, we observed increased expression of DOR in cortex, hippocampus, and striatum; suggesting a role for these forebrain regions in the regulation of migraine. To test this hypothesis, we used conditional knockout mice with DORs deleted from forebrain GABAergic neurons (Dlx-DOR), and investigated the outcome of this knockout on the effectiveness of the DOR agonist SNC80 in multiple headache models. In DOR loxP controls SNC80 blocked the development of acute and chronic cephalic allodynia in the chronic nitroglycerin model, an effect that was lost in Dlx-DOR mice. In addition, the anti-allodynic effects of SNC80 were lost in a model of opioid induced hyperalgesia/medication overuse headache in Dlx-DOR conditional knockouts. In a model reflecting negative affect associated with migraine, SNC80 was only effective in loxP controls and not Dlx-DOR mice. Similarly, SNC80 was ineffective in the cortical spreading depression model of migraine aura in conditional knockout mice. Taken together, these data indicate that forebrain DORs are necessary for the action of DOR agonists in relieving headache-related symptoms and suggest that forebrain regions may play an important role in migraine modulation.
Identifiants
pubmed: 33077757
doi: 10.1038/s41598-020-74605-9
pii: 10.1038/s41598-020-74605-9
pmc: PMC7573615
doi:
Substances chimiques
Analgesics, Opioid
0
Benzamides
0
Piperazines
0
Receptors, Opioid, delta
0
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide
156727-74-1
Nitroglycerin
G59M7S0WS3
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
17629Subventions
Organisme : NIDA NIH HHS
ID : R01 DA040688
Pays : United States
Organisme : NIDA NIH HHS
ID : DA040688
Pays : United States
Organisme : NINDS NIH HHS
ID : NS109862
Pays : United States
Références
Front Syst Neurosci. 2018 Dec 18;12:63
pubmed: 30618656
Neurology. 2020 Aug 4;95(5):e457-e468
pubmed: 32527971
Trends Neurosci. 1988 Jul;11(7):308-14
pubmed: 2465635
Mol Cell Proteomics. 2019 Dec;18(12):2447-2458
pubmed: 31649062
Br J Pharmacol. 2015 Jul;172(14):3461-71
pubmed: 26114403
Cephalalgia. 2017 Dec;37(14):1350-1372
pubmed: 27852962
Pain. 2009 Apr;142(3):179-82
pubmed: 19232469
Neuropharmacology. 2019 Apr;148:77-86
pubmed: 30553828
Physiol Rev. 2009 Oct;89(4):1379-412
pubmed: 19789384
Mol Pain. 2013 Mar 04;9:8
pubmed: 23497324
Behav Brain Res. 2015 Feb 1;278:429-34
pubmed: 25447299
J Neurosci. 2006 Jan 18;26(3):953-62
pubmed: 16421315
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
J Neurophysiol. 2007 Jun;97(6):4143-51
pubmed: 17329631
J Neurosci. 1997 May 15;17(10):3751-65
pubmed: 9133395
J Pharmacol Exp Ther. 2012 Sep;342(3):799-807
pubmed: 22700431
Headache. 2017 Oct;57(9):1340-1358
pubmed: 28842982
Curr Opin Neurol. 2016 Jun;29(3):314-9
pubmed: 27023737
Pain. 2011 Jun;152(6):1238-48
pubmed: 21295407
Nat Rev Neurol. 2013 Nov;9(11):637-44
pubmed: 24042483
J Neurosci. 2017 Apr 5;37(14):3741-3752
pubmed: 28264976
Experientia. 1985 May 15;41(5):625-7
pubmed: 2987021
J Neurosci. 2010 Jun 30;30(26):8807-14
pubmed: 20592202
Methods Mol Biol. 2015;1230:87-104
pubmed: 25293318
Nat Med. 2002 Feb;8(2):136-42
pubmed: 11821897
Ann Neurol. 2007 Jun;61(6):603-6
pubmed: 17474110
Brain. 2010 Apr;133(Pt 4):996-1012
pubmed: 20348134
J Neurosci. 2003 Mar 15;23(6):2075-85
pubmed: 12657666
Ann Neurol. 2006 Apr;59(4):652-61
pubmed: 16450381
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13117-22
pubmed: 20615975
Trends Pharmacol Sci. 2011 Oct;32(10):581-90
pubmed: 21925742
Pain. 2017 Apr;158 Suppl 1:S43-S49
pubmed: 28106670
Pain. 1989 Jul;38(1):17-24
pubmed: 2506503
Cephalalgia. 2019 Jan;39(1):77-90
pubmed: 29771142
Br J Pharmacol. 2014 May;171(9):2375-84
pubmed: 24467301
Headache. 2012 Jan;52(1):18-36
pubmed: 22268775
Neurology. 2017 Apr 25;88(17):1634-1641
pubmed: 28356463
Ann Neurol. 2011 May;69(5):855-65
pubmed: 21416489
J Comp Neurol. 2005 Jan 24;481(4):416-26
pubmed: 15593339
Pain. 2003 Jan;101(1-2):199-208
pubmed: 12507715
Brain Res. 1981 Apr 6;210(1-2):243-52
pubmed: 7225810
Br J Pharmacol. 2018 Mar;175(6):891-901
pubmed: 29278419
Neuron. 2006 Aug 17;51(4):455-66
pubmed: 16908411
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
Hippocampus. 2003;13(7):835-44
pubmed: 14620879
J Neurosci. 2005 Sep 28;25(39):8825-32
pubmed: 16192372
J Comp Neurol. 2003 Oct 20;465(3):349-60
pubmed: 12966560
J Neurosci. 2003 Jan 1;23(1):167-74
pubmed: 12514213
J Neurosci. 2010 Dec 8;30(49):16459-68
pubmed: 21147985
Pain. 2007 Jan;127(1-2):84-93
pubmed: 16963185
Cephalalgia. 2018 Jul;38(8):1471-1484
pubmed: 29022756
J Neurosci. 2016 Apr 27;36(17):4733-43
pubmed: 27122032
J Neurosci. 2017 Nov 22;37(47):11431-11440
pubmed: 29066554
Pain. 2014 Feb;155(2):269-74
pubmed: 24121068
Biol Psychiatry. 2015 Feb 15;77(4):404-15
pubmed: 25444168
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9691-6
pubmed: 16766653
Nat Rev Neurol. 2017 Dec;13(12):713-724
pubmed: 28984313